99.1
|
Press Release: Kamada Reports Second Quarter 2014 Financial Results
|
99.2
|
Kamada Ltd.’s Consolidated Financial Statements as of June 30, 2014 (Unaudited)
|
99.3
|
Disclosure for Debenture Holders as of June 30, 2014
|
SIGNATURE
|
Date: August 14, 2014 |
KAMADA LTD.
|
||
|
By:
|
/s/ Gil Efron | |
Gil Efron
|
|||
Chief Financial Officer
|
|||
EXHIBIT NO.
|
DESCRIPTION
|
99.1
|
Press Release: Kamada Reports Second Quarter 2014 Financial Results
|
99.2 | Kamada Ltd.’s Consolidated Financial Statements as of June 30, 2014 (Unaudited) |
99.3 | Disclosure for Debenture Holders as of June 30, 2014 |
News Release | ![]() |
|
·
|
Revenues for the quarter were $15.8 million compared with $16.1 million for the second quarter of 2013; the second quarter of 2013 included a one-time payment of $4.5 million received from Baxter International Inc. (Baxter) related to a technology transfer milestone
|
|
·
|
Gross loss for the quarter of $0.10 million compared with gross profit of $7.4 million in the year-ago second quarter; excluding a one-time $3.0 million write-off of inventory in the current quarter and the one-time payment from Baxter in the prior-year quarter, gross profit for the second quarter of 2014 was $3.0 million, compared with $2.9 million in the second quarter of 2013
|
|
·
|
Introducing 2014 revenue guidance, with total revenue for the year ending December 31, 2014 expected to be between $70 million and $72 million
|
|
·
|
Received approval from the U.S. Food and Drug Administration (FDA) for enhancements to the Company’s manufacturing process that significantly improve capacity for the production of its Alpha-1 Antitrypsin (AAT) therapeutics
|
|
·
|
Announced preliminary top-line results from the Phase 2/3 pivotal clinical trial in Europe and Canada of the Company’s proprietary inhaled AAT therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema), with final results expected in September 2014
|
|
·
|
Received FDA approval for a significantly improved infusion rate for Glassia® (Alpha-1-Proteinase Inhibitor - Human), the first and only ready-to-use liquid alpha-1-proteinase inhibitor indicated as a chronic augmentation and maintenance therapy in adults with AATD, marketed in the U.S. by Baxter
|
|
·
|
Announced a proof-of-concept study with Glassia to treat graft-versus-host disease (GVHD) in cooperation with Baxter; the study is being conducted at the Fred Hutchinson Cancer Research Center in Seattle
|
Contacts:
Gil Efron
CFO
ir@kamada.com
|
Anne Marie Fields
LHA
212-838-3777
afields@lhai.com
|
As of June 30,
|
As of December 31,
|
|||||||||||
2014
|
2013
|
2013
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
In thousands
|
||||||||||||
Current Assets
|
||||||||||||
Cash and cash equivalents
|
$ | 25,083 | $ | 73,403 | $ | 59,110 | ||||||
Short-term investments
|
42,603 | 9,152 | 15,067 | |||||||||
Trade receivables, net
|
15,215 | 12,340 | 17,882 | |||||||||
Other accounts receivables
|
2,299 | 1,400 | 3,694 | |||||||||
Inventories
|
23,871 | 23,901 | 21,933 | |||||||||
109,071 | 120,196 | 117,686 | ||||||||||
Non-Current Assets | ||||||||||||
Long-term inventories
|
- | 165 | - | |||||||||
Property, plant and equipment, net
|
21,668 | 19,993 | 21,443 | |||||||||
Other long-term assets
|
160 | 193 | 250 | |||||||||
21,828 | 20,351 | 21,693 | ||||||||||
130,899 | 140,547 | 139,379 | ||||||||||
Current Liabilities | ||||||||||||
Short term credit and Current maturities of convertible debentures
|
8,798 | 5,534 | 8,718 | |||||||||
Trade payables
|
15,942 | 9,098 | 14,093 | |||||||||
Other accounts payables
|
4,510 | 5,481 | 4,313 | |||||||||
Deferred revenues
|
5,264 | 8,596 | 5,454 | |||||||||
34,514 | 28,709 | 32,578 | ||||||||||
Non-Current Liabilities
|
||||||||||||
Convertible debentures
|
8,039 | 19,930 | 7,498 | |||||||||
Employee benefit liabilities, net
|
834 | 770 | 827 | |||||||||
Deferred revenues
|
6,867 | 10,149 | 8,506 | |||||||||
15,740 | 30,849 | 16,831 | ||||||||||
Equity
|
||||||||||||
Share capital
|
9,203 | 8,983 | 9,201 | |||||||||
Share premium
|
157,212 | 148,655 | 157,100 | |||||||||
Conversion option in convertible debentures
|
2,217 | 3,794 | 2,218 | |||||||||
Capital reserve due to translation to presentation currency
|
(3,490 | ) | (3,490 | ) | (3,490 | ) | ||||||
Capital reserve from hedges
|
54 | 121 | 156 | |||||||||
Capital reserve from available for sale financial assets
|
93 | - | (27 | ) | ||||||||
Capital reserve from share-based payments
|
7,217 | 4,903 | 5,189 | |||||||||
Capital reserve from employee benefits
|
(129 | ) | (141 | ) | (129 | ) | ||||||
Accumulated deficit
|
(91,732 | ) | (81,836 | ) | (80,248 | ) | ||||||
80,645 | 80,989 | 89,970 | ||||||||||
$ | 130,899 | $ | 140,547 | $ | 139,379 |
Six months period
ended
June 30,
|
Three months period
ended
June 30,
|
Year ended
December 31
|
||||||||||||||||||
2014
|
2013
|
2014
|
2013
|
2013
|
||||||||||||||||
Unaudited
|
Audited
|
|||||||||||||||||||
Thousands of US dollar (Except for per-share income (loss) data)
|
||||||||||||||||||||
Revenues from proprietary products
|
$ | 16,142 | $ | 19,957 | $ | 8,721 | $ | 11,897 | $ | 50,658 | ||||||||||
Revenues from distribution
|
12,842 | 8,754 | 7,076 | 4,218 | 19,965 | |||||||||||||||
Total revenues
|
28,984 | 28,711 | 15,797 | 16,115 | 70,623 | |||||||||||||||
Cost of revenues from proprietary products
|
14,706 | 9,682 | 9,703 | 5,121 | 27,104 | |||||||||||||||
Cost of revenues from distribution
|
11,082 | 7,412 | 6,160 | 3,573 | 17,112 | |||||||||||||||
Total cost of revenues
|
25,788 | 17,094 | 15,863 | 8,694 | 44,216 | |||||||||||||||
Gross profit (loss)
|
3,196 | 11,617 | (66 | ) | 7,421 | 26,407 | ||||||||||||||
Research and development expenses
|
8,433 | 6,334 | 5,068 | 2,604 | 12,745 | |||||||||||||||
Selling and marketing expenses
|
1,366 | 963 | 719 | 450 | 2,100 | |||||||||||||||
General and administrative expenses
|
3,994 | 3,975 | 2,037 | 2,719 | 7,862 | |||||||||||||||
Operating income (loss)
|
(10,597 | ) | 345 | (7,890 | ) | 1,648 | 3,700 | |||||||||||||
Financial income
|
421 | 165 | 179 | 79 | 289 | |||||||||||||||
Income (expense) in respect of currency exchange and translation differences and derivatives instruments, net
|
136 | (70 | ) | 97 | (132 | ) | (369 | ) | ||||||||||||
Financial expense
|
(1,410 | ) | (1,549 | ) | (737 | ) | (693 | ) | (3,153 | ) | ||||||||||
Income (loss) before taxes on income
|
(11,450 | ) | (1,109 | ) | (8,351 | ) | 902 | 467 | ||||||||||||
Taxes on income
|
34 | 36 | 11 | 12 | 24 | |||||||||||||||
Net Income (loss)
|
(11,484 | ) | (1,145 | ) | (8,362 | ) | 890 | 443 | ||||||||||||
Other Comprehensive Income (loss):
|
||||||||||||||||||||
Items that may be reclassified to profit or loss in subsequent periods:
|
||||||||||||||||||||
Net gain (loss) on available for sale financial assets
|
120 | - | 81 | - | (27 | ) | ||||||||||||||
Net loss on cash flow hedge
|
(102 | ) | (108 | ) | (33 | ) | (67 | ) | (73 | ) | ||||||||||
Items that will not be reclassified to profit or loss in subsequent periods:
|
||||||||||||||||||||
Actuarial net gain of defined benefit plans
|
- | - | - | - | 12 | |||||||||||||||
Total comprehensive income (loss)
|
$ | (11,466 | ) | $ | (1,253 | ) | $ | (8,314 | ) | $ | 823 | $ | 355 | |||||||
Income (loss) per share attributable to equity holders of the Company:
|
||||||||||||||||||||
Basic income (loss) per share
|
$ | (0.32 | ) | $ | (0.04 | ) | $ | (0.23 | ) | $ | (0.03 | ) | $ | 0.01 | ||||||
Diluted income (loss) per share
|
$ | (0.32 | ) | $ | (0.04 | ) | $ | (0.23 | ) | $ | (0.03 | ) | $ | 0.01 |
Six months period Ended
June 30,
|
Three months period Ended
June 30,
|
Year Ended
December 31,
|
||||||||||||||||||
2014 | 2013 | 2014 | 2013 | 2013 | ||||||||||||||||
Unaudited | Audited | |||||||||||||||||||
Thousands of US dollar | ||||||||||||||||||||
Cash Flows from Operating Activities
|
||||||||||||||||||||
Net income (loss)
|
$ | (11,484 | ) | $ | (1,145 | ) | $ | (8,362 | ) | $ | 890 | $ | 443 | |||||||
Adjustments to reconcile loss to net cash provided by (used in) operating activities:
|
||||||||||||||||||||
Adjustments to the profit or loss items:
|
||||||||||||||||||||
Depreciation and amortization
|
1,315 | 1,515 | 652 | 692 | 3,001 | |||||||||||||||
Finance expenses, net
|
853 | 1,454 | 461 | 747 | 3,233 | |||||||||||||||
Cost of share-based payment
|
2,095 | 649 | 1,009 | 436 | 1,327 | |||||||||||||||
Loss from sale of fixed assets
|
- | 67 | - | 67 | 24 | |||||||||||||||
Taxes on income
|
34 | 36 | 11 | 12 | 73 | |||||||||||||||
Change in employee benefit liabilities, net
|
7 | 52 | 33 | 32 | 121 | |||||||||||||||
4,304 | 3,773 | 2,166 | 1,986 | 7,779 | ||||||||||||||||
Changes in asset and liability items:
|
||||||||||||||||||||
Decrease (increase) in trade receivables
|
2,764 | 1,743 | (2,472 | ) | (3,097 | ) | (3,445 | ) | ||||||||||||
Decrease (increase) in other accounts receivables
|
530 | 207 | 770 | 649 | (444 | ) | ||||||||||||||
Decrease (increase) in inventories and long-term inventories
|
(1,938 | ) | (3,315 | ) | 4,743 | (85 | ) | (1,182 | ) | |||||||||||
Decrease (increase) in deferred expenses
|
814 | 28 | 255 | 139 | (1,231 | ) | ||||||||||||||
Increase (decrease) in trade payables
|
1,898 | (3,178 | ) | (342 | ) | (3,716 | ) | 1,579 | ||||||||||||
Increase (decrease) in other accounts payables
|
196 | 960 | 759 | 1,190 | 264 | |||||||||||||||
Decrease in deferred revenues
|
(1,829 | ) | (1,485 | ) | (983 | ) | (1,351 | ) | (6,270 | ) | ||||||||||
2,435 | (5,040 | ) | 2,730 | (6,271 | ) | (10,729 | ) | |||||||||||||
Cash paid and received during the period for:
|
||||||||||||||||||||
Interest paid
|
(602 | ) | (1,062 | ) | (301 | ) | (527 | ) | (1,968 | ) | ||||||||||
Interest received
|
132 | 195 | 38 | 112 | 663 | |||||||||||||||
Taxes paid
|
(64 | ) | (54 | ) | (4 | ) | (23 | ) | (42 | ) | ||||||||||
(534 | ) | (921 | ) | (267 | ) | (438 | ) | (1,347 | ) | |||||||||||
Net cash used in operating activities
|
$ | (5,279 | ) | $ | (3,333 | ) | $ | (3,733 | ) | $ | (3,833 | ) | $ | (3,854 | ) |
Six months period Ended
June 30,
|
Three months period Ended
June 30,
|
Year Ended
December 31,
|
||||||||||||||||||
2014 | 2013 | 2014 | 2013 | 2013 | ||||||||||||||||
Unaudited | Audited | |||||||||||||||||||
Thousands of US dollar | ||||||||||||||||||||
Cash Flows from Investing Activities
|
||||||||||||||||||||
Short-term investments
|
$ | (26,784 | ) | $ | 7,848 | $ | (3,352 | ) | $ | 1,279 | $ | 1,732 | ||||||||
Purchase of property and equipment
|
(1,535 | ) | (2,747 | ) | (919 | ) | (1,473 | ) | (5,643 | ) | ||||||||||
Proceeds from sale of equipment
|
- | 3 | - | 3 | 8 | |||||||||||||||
Net cash provided by (used in) investing activities
|
(28,319 | ) | 5,104 | (4,271 | ) | (191 | ) | (3,903 | ) | |||||||||||
Cash Flows from Financing Activities
|
||||||||||||||||||||
Exercise of options into shares
|
39 | 309 | 39 | 136 | 562 | |||||||||||||||
Proceeds from issuance of ordinary shares, net
|
- | 53,958 | - | 54,479 | 52,953 | |||||||||||||||
Short term credit from bank and others, net
|
- | (6 | ) | - | (6 | ) | (12 | ) | ||||||||||||
Repayment of convertible debentures
|
- | - | - | - | (4,295 | ) | ||||||||||||||
Net cash provided by financing activities
|
39 | 54,261 | 39 | 54,609 | 49,208 | |||||||||||||||
Exchange differences on balances of cash and cash equivalent
|
(468 | ) | 505 | (266 | ) | 177 | 793 | |||||||||||||
Increase (decrease) in cash and cash equivalents
|
(34,024 | ) | 56,537 | (8,231 | ) | 50,762 | 42,244 | |||||||||||||
Cash and cash equivalents at the beginning of the period
|
59,110 | 16,866 | 33,314 | 22,641 | 16,866 | |||||||||||||||
Cash and cash equivalents at the end of the period
|
$ | 25,083 | $ | 73,403 | $ | 25,083 | $ | 73,403 | $ | 59,110 | ||||||||||
Significant non-cash transactions
|
||||||||||||||||||||
Purchase of property, equipment and intangible assets on credit
|
$ | - | $ | - | $ | - | $ | - | $ | 151 | ||||||||||
Exercise of options presented as liability
|
$ | - | $ | 23 | $ | - | $ | - | $ | 23 | ||||||||||
Exercise of convertible debentures into shares
|
$ | 7 | $ | - | $ | - | $ | - | $ | 6,508 | ||||||||||
Issuance expenses accrued in other accounts payables
|
$ | - | $ | 1,094 | $ | - | $ | 994 | $ | - |
Six months period
Ended June 30
|
Three months period
Ended June 30
|
Year ended
December 31
|
||||||||||||||||||
2014
|
2013
|
2014
|
2013
|
2013 | ||||||||||||||||
Thousands of US dollar
|
||||||||||||||||||||
Net Income (loss)
|
$ | (11,484 | ) | $ | (1,145 | ) | $ | (8,362 | ) | $ | 890 | $ | 443 | |||||||
Income tax expense
|
34 | 36 | 11 | 12 | 24 | |||||||||||||||
Financial expense, net
|
853 | 1,384 | 461 | 614 | 2,864 | |||||||||||||||
Depreciation and amortization expense
|
1,315 | 1,515 | 652 | 692 | 3,001 | |||||||||||||||
Share-based compensation charges
|
2,095 | 649 | 1,009 | 436 | 1,327 | |||||||||||||||
Expense (income) in respect of translation differences and derivatives instruments, net
|
- | 70 | - | 132 | 369 | |||||||||||||||
one-time management compensation
|
1,386 | 1,386 | 1,386 | |||||||||||||||||
Adjusted EBITDA
|
$ | (7,187 | ) | $ | 3,895 | $ | (6,229 | ) | $ | 4,162 | $ | 9,414 |
Six months period
Ended June 30
|
Three months period
Ended June 30
|
Year ended
December 31
|
||||||||||||||||||
2014
|
2013
|
2014
|
2013
|
2013
|
||||||||||||||||
Thousands of US dollar
|
||||||||||||||||||||
Net income (loss)
|
$ | (11,484 | ) | $ | (1,145 | ) | $ | (8,362 | ) | $ | 890 | $ | 443 | |||||||
Share-based compensation charges
|
2,095 | 649 | 1,009 | 436 | 1,327 | |||||||||||||||
One time management compensation
|
1,386 | 1,386 | 1,386 | |||||||||||||||||
Adjusted net income
|
$ | (9,389 | ) | $ | 890 | $ | (7,353 | ) | $ | 2,712 | $ | 3,156 |
Page
|
|
2
|
|
3
|
|
4-6
|
|
7-8
|
|
9-13
|
KAMADA LTD.
|
As of June 30,
|
As of December 31,
|
|||||||||||
2014
|
2013
|
2013
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
In thousands
|
||||||||||||
Current Assets
|
||||||||||||
Cash and cash equivalents
|
$ | 25,083 | $ | 73,403 | $ | 59,110 | ||||||
Short-term investments
|
42,603 | 9,152 | 15,067 | |||||||||
Trade receivables, net
|
15,215 | 12,340 | 17,882 | |||||||||
Other accounts receivables
|
2,299 | 1,400 | 3,694 | |||||||||
Inventories
|
23,871 | 23,901 | 21,933 | |||||||||
109,071 | 120,196 | 117,686 | ||||||||||
Non-Current Assets | ||||||||||||
Long-term inventories
|
- | 165 | - | |||||||||
Property, plant and equipment, net
|
21,668 | 19,993 | 21,443 | |||||||||
Other long-term assets
|
160 | 193 | 250 | |||||||||
21,828 | 20,351 | 21,693 | ||||||||||
130,899 | 140,547 | 139,379 | ||||||||||
Current Liabilities | ||||||||||||
Short term credit and Current maturities of convertible debentures
|
8,798 | 5,534 | 8,718 | |||||||||
Trade payables
|
15,942 | 9,098 | 14,093 | |||||||||
Other accounts payables
|
4,510 | 5,481 | 4,313 | |||||||||
Deferred revenues
|
5,264 | 8,596 | 5,454 | |||||||||
34,514 | 28,709 | 32,578 | ||||||||||
Non-Current Liabilities
|
||||||||||||
Convertible debentures
|
8,039 | 19,930 | 7,498 | |||||||||
Employee benefit liabilities, net
|
834 | 770 | 827 | |||||||||
Deferred revenues
|
6,867 | 10,149 | 8,506 | |||||||||
15,740 | 30,849 | 16,831 | ||||||||||
Equity
|
||||||||||||
Share capital
|
9,203 | 8,983 | 9,201 | |||||||||
Share premium
|
157,212 | 148,655 | 157,100 | |||||||||
Conversion option in convertible debentures
|
2,217 | 3,794 | 2,218 | |||||||||
Capital reserve due to translation to presentation currency
|
(3,490 | ) | (3,490 | ) | (3,490 | ) | ||||||
Capital reserve from hedges
|
54 | 121 | 156 | |||||||||
Capital reserve from available for sale financial assets
|
93 | - | (27 | ) | ||||||||
Capital reserve from share-based payments
|
7,217 | 4,903 | 5,189 | |||||||||
Capital reserve from employee benefits
|
(129 | ) | (141 | ) | (129 | ) | ||||||
Accumulated deficit
|
(91,732 | ) | (81,836 | ) | (80,248 | ) | ||||||
80,645 | 80,989 | 89,970 | ||||||||||
$ | 130,899 | $ | 140,547 | $ | 139,379 |
Six months period ended
June 30,
|
Three months period ended
June 30,
|
Year ended
December 31
|
||||||||||||||||||
2014
|
2013
|
2014
|
2013
|
2013
|
||||||||||||||||
Unaudited
|
Audited
|
|||||||||||||||||||
Thousands of US dollar (Except for per-share income (loss) data)
|
||||||||||||||||||||
Revenues from proprietary products
|
$ | 16,142 | $ | 19,957 | $ | 8,721 | $ | 11,897 | $ | 50,658 | ||||||||||
Revenues from distribution
|
12,842 | 8,754 | 7,076 | 4,218 | 19,965 | |||||||||||||||
Total revenues
|
28,984 | 28,711 | 15,797 | 16,115 | 70,623 | |||||||||||||||
Cost of revenues from proprietary products
|
14,706 | 9,682 | 9,703 | 5,121 | 27,104 | |||||||||||||||
Cost of revenues from distribution
|
11,082 | 7,412 | 6,160 | 3,573 | 17,112 | |||||||||||||||
Total cost of revenues
|
25,788 | 17,094 | 15,863 | 8,694 | 44,216 | |||||||||||||||
Gross profit (loss)
|
3,196 | 11,617 | (66 | ) | 7,421 | 26,407 | ||||||||||||||
Research and development expenses
|
8,433 | 6,334 | 5,068 | 2,604 | 12,745 | |||||||||||||||
Selling and marketing expenses
|
1,366 | 963 | 719 | 450 | 2,100 | |||||||||||||||
General and administrative expenses
|
3,994 | 3,975 | 2,037 | 2,719 | 7,862 | |||||||||||||||
Operating income (loss)
|
(10,597 | ) | 345 | (7,890 | ) | 1,648 | 3,700 | |||||||||||||
Financial income
|
421 | 165 | 179 | 79 | 289 | |||||||||||||||
Income (expense) in respect of currency exchange and translation differences and derivatives instruments, net
|
136 | (70 | ) | 97 | (132 | ) | (369 | ) | ||||||||||||
Financial expense
|
(1,410 | ) | (1,549 | ) | (737 | ) | (693 | ) | (3,153 | ) | ||||||||||
Income (loss) before taxes on income
|
(11,450 | ) | (1,109 | ) | (8,351 | ) | 902 | 467 | ||||||||||||
Taxes on income
|
34 | 36 | 11 | 12 | 24 | |||||||||||||||
Net Income (loss)
|
(11,484 | ) | (1,145 | ) | (8,362 | ) | 890 | 443 | ||||||||||||
Other Comprehensive Income (loss):
|
||||||||||||||||||||
Items that may be reclassified to profit or loss in subsequent periods:
|
||||||||||||||||||||
Net gain (loss) on available for sale financial assets
|
120 | - | 81 | - | (27 | ) | ||||||||||||||
Net loss on cash flow hedge
|
(102 | ) | (108 | ) | (33 | ) | (67 | ) | (73 | ) | ||||||||||
Items that will not be reclassified to profit or loss in subsequent periods:
|
||||||||||||||||||||
Actuarial net gain of defined benefit plans
|
- | - | - | - | 12 | |||||||||||||||
Total comprehensive income (loss)
|
$ | (11,466 | ) | $ | (1,253 | ) | $ | (8,314 | ) | $ | 823 | $ | 355 | |||||||
Income (loss) per share attributable to equity holders of the Company:
|
||||||||||||||||||||
Basic income (loss) per share
|
$ | (0.32 | ) | $ | (0.04 | ) | $ | (0.23 | ) | $ | (0.03 | ) | $ | 0.01 | ||||||
Diluted income (loss) per share
|
$ | (0.32 | ) | $ | (0.04 | ) | $ | (0.23 | ) | $ | (0.03 | ) | $ | 0.01 |
Share Capital
|
Share premium
|
Conversion option in convertible debentures
|
Capital reserve from available for sale financial assets
|
Capital reserve due to translation to presentation currency
|
Capital reserve from hedges
|
Capital reserve from share-based payments
|
Capital reserve from employee benefits
|
Accumulated deficit
|
Total equity
|
|||||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||||||||||||
In thousands | ||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2014
|
$ | 9,201 | $ | 157,100 | $ | 2,218 | $ | (27 | ) | $ | (3,490 | ) | $ | 156 | $ | 5,189 | $ | (129 | ) | $ | (80,248 | ) | $ | 89,970 | ||||||||||||||||
Net loss
|
- | - | - | - | - | - | - | - | (11,484 | ) | (11,484 | ) | ||||||||||||||||||||||||||||
Other comprehensive income (loss)
|
- | - | - | 120 | - | (102 | ) | - | - | - | 18 | |||||||||||||||||||||||||||||
Total comprehensive income (loss)
|
- | - | - | 120 | - | (102 | ) | - | - | (11,484 | ) | (11,466 | ) | |||||||||||||||||||||||||||
Exercise of options into shares, net
|
2 | 104 | - | - | - | - | (67 | ) | - | - | 39 | |||||||||||||||||||||||||||||
Conversion of convertible debentures into shares
|
* | ) | 8 | (1 | ) | - | - | - | - | - | - | 7 | ||||||||||||||||||||||||||||
Cost of share-based payment
|
- | - | - | - | - | - | 2,095 | - | - | 2,095 | ||||||||||||||||||||||||||||||
Balance as of June 30, 2014
|
$ | 9,203 | $ | 157,212 | $ | 2,217 | $ | 93 | $ | (3,490 | ) | $ | 54 | $ | 7,217 | $ | (129 | ) | $ | (91,732 | ) | $ | 80,645 |
Share Capital
|
Share premium
|
Conversion option in convertible debentures
|
Capital reserve due to translation to presentation currency
|
Capital reserve from hedges
|
Capital reserve from share-based payments
|
Capital reserve from employee benefits
|
Accumulated deficit
|
Total equity
|
||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||||||||
In thousands | ||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2013
|
$ | 7,204 | $ | 96,874 | $ | 3,794 | $ | (3,490 | ) | $ | 229 | $ | 4,614 | $ | (141 | ) | $ | (80,691 | ) | $ | 28,393 | |||||||||||||||
Net loss
|
- | - | - | - | - | - | - | (1,145 | ) | (1,145 | ) | |||||||||||||||||||||||||
Other comprehensive loss
|
- | - | - | - | (108 | ) | - | - | - | (108 | ) | |||||||||||||||||||||||||
Total comprehensive loss
|
- | - | - | - | (108 | ) | - | - | (1,145 | ) | (1,253 | ) | ||||||||||||||||||||||||
Issuance of ordinary shares, net of issuance costs
|
1,749 | 51,115 | - | - | - | - | - | - | 52,864 | |||||||||||||||||||||||||||
Exercise of options into shares, net
|
30 | 662 | - | - | - | (360 | ) | - | - | 332 | ||||||||||||||||||||||||||
Conversion of convertible debentures into shares
|
4 | * | ) | - | - | - | - | - | - | 4 | ||||||||||||||||||||||||||
Cost of share-based payment
|
- | - | - | - | - | 649 | - | - | 649 | |||||||||||||||||||||||||||
Balance as of June 30, 2013
|
$ | 8,983 | $ | 148,655 | $ | 3,794 | $ | (3,490 | ) | $ | 121 | $ | 4,903 | $ | (141 | ) | $ | (81,836 | ) | $ | 80,989 |
Share Capital
|
Share premium
|
Conversion option in convertible debentures
|
Capital reserve from available for sale financial assets
|
Capital reserve due to translation to presentation currency
|
Capital reserve from hedges
|
Capital reserve from share-based payments
|
Capital reserve from employee benefits
|
Accumulated deficit
|
Total equity
|
|||||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||||||||||||
In thousands | ||||||||||||||||||||||||||||||||||||||||
Balance as of April 1, 2014
|
$ | 9,201 | $ | 157,117 | $ | 2,217 | $ | 12 | $ | (3,490 | ) | $ | 87 | $ | 6,266 | $ | (129 | ) | $ | (83,370 | ) | $ | 87,911 | |||||||||||||||||
Net loss
|
- | - | - | - | - | - | - | - | (8,362 | ) | (8,362 | ) | ||||||||||||||||||||||||||||
Other comprehensive income (loss)
|
- | - | - | 81 | - | (33 | ) | - | - | - | 48 | |||||||||||||||||||||||||||||
Total comprehensive income (loss)
|
- | - | - | 81 | - | (33 | ) | - | - | (8,362 | ) | (8,314 | ) | |||||||||||||||||||||||||||
Exercise of options into shares, net
|
2 | 95 | - | - | - | - | (58 | ) | - | - | 39 | |||||||||||||||||||||||||||||
Cost of share-based payment
|
- | - | - | - | - | - | 1,009 | - | - | 1,009 | ||||||||||||||||||||||||||||||
Balance as of June 30, 2014
|
$ | 9,203 | $ | 157,212 | $ | 2,217 | $ | 93 | $ | (3,490 | ) | $ | 54 | $ | 7,217 | $ | (129 | ) | $ | (91,732 | ) | $ | 80,645 |
Share Capital
|
Share premium
|
Conversion option in convertible debentures
|
Capital reserve due to translation to presentation currency
|
Capital reserve from hedges
|
Capital reserve from share-based payments
|
Capital reserve from employee benefits
|
Accumulated
deficit
|
Total equity
|
||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||||||||
In thousands | ||||||||||||||||||||||||||||||||||||
Balance as of April 1, 2013
|
$ | 7,220 | $ | 97,185 | $ | 3,794 | $ | (3,490 | ) | $ | 188 | $ | 4,696 | $ | (141 | ) | $ | (82,726 | ) | $ | 26,726 | |||||||||||||||
Net income
|
- | - | - | - | - | - | - | 890 | 890 | |||||||||||||||||||||||||||
Other comprehensive income (loss)
|
- | - | - | - | (67 | ) | - | - | - | (67 | ) | |||||||||||||||||||||||||
Total comprehensive income (loss)
|
- | - | - | - | (67 | ) | - | - | 890 | 823 | ||||||||||||||||||||||||||
Issuance of ordinary shares, net of issuance costs
|
1,749 | 51,115 | - |
-
|
- | - | - | - | 52,864 | |||||||||||||||||||||||||||
Exercise of options into shares, net
|
14 | 351 | - | - | - | (229 | ) | - | - | 136 | ||||||||||||||||||||||||||
Conversion of convertible debentures into shares
|
* | ) | 4 | * | ) | - | - | - | - | - | 4 | |||||||||||||||||||||||||
Cost of share-based payment
|
- | - | - | - | - | 436 | - | - | 436 | |||||||||||||||||||||||||||
Balance as of June 30, 2013
|
$ | 8,983 | $ | 148,655 | $ | 3,794 | $ | (3,490 | ) | $ | 121 | $ | 4,903 | $ | (141 | ) | $ | (81,836 | ) | $ | 80,989 |
Share Capital
|
Share premium
|
Conversion option in convertible debentures
|
Capital reserve from available for sale financial assets
|
Capital reserve due to translation to presentation currency
|
Capital reserve from hedges
|
Capital reserve from share-based payments
|
Capital reserve from employee benefits
|
Accumulated deficit
|
Total equity
|
|||||||||||||||||||||||||||||||
Audited | ||||||||||||||||||||||||||||||||||||||||
In thousands | ||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2013
|
$ | 7,204 | $ | 96,874 | $ | 3,794 | $ | - | $ | (3,490 | ) | $ | 229 | $ | 4,614 | $ | (141 | ) | $ | (80,691 | ) | $ | 28,393 | |||||||||||||||||
Net income
|
- | - | - | - | - | - | - | - | 443 | 443 | ||||||||||||||||||||||||||||||
Other comprehensive income (loss)
|
- | - | - | (27 | ) | - | (73 | ) | - | 12 | - | (88 | ) | |||||||||||||||||||||||||||
Total comprehensive income (loss)
|
- | - | - | (27 | ) | - | (73 | ) | - | 12 | 443 | 355 | ||||||||||||||||||||||||||||
Exercise of warrants and options into shares
|
62 | 1,275 | - | - | - | - | (752 | ) | - | - | 585 | |||||||||||||||||||||||||||||
Issuance of ordinary shares, net of issuance costs
|
1,749 | 51,053 | - | - | - | - | - | - | - | 52,802 | ||||||||||||||||||||||||||||||
Conversion of convertible debentures into shares
|
186 | 7,898 | (1,576 | ) | - | - | - | - | - | - | 6,508 | |||||||||||||||||||||||||||||
Cost of share-based payment
|
- | - | - | - | - | - | 1,327 | - | - | 1,327 | ||||||||||||||||||||||||||||||
Balance as of December 31, 2013
|
$ | 9,201 | $ | 157,100 | $ | 2,218 | $ | (27 | ) | $ | (3,490 | ) | $ | 156 | $ | 5,189 | $ | (129 | ) | $ | (80,248 | ) | $ | 89,970 |
Six months period Ended
June 30,
|
Three months period Ended
June 30,
|
Year Ended
December 31,
|
||||||||||||||||||
2014 | 2013 | 2014 | 2013 | 2013 | ||||||||||||||||
Unaudited | Audited | |||||||||||||||||||
Thousands of US dollar | ||||||||||||||||||||
Cash Flows from Operating Activities
|
||||||||||||||||||||
Net income (loss)
|
$ | (11,484 | ) | $ | (1,145 | ) | $ | (8,362 | ) | $ | 890 | $ | 443 | |||||||
Adjustments to reconcile loss to net cash provided by (used in) operating activities:
|
||||||||||||||||||||
Adjustments to the profit or loss items:
|
||||||||||||||||||||
Depreciation and amortization
|
1,315 | 1,515 | 652 | 692 | 3,001 | |||||||||||||||
Finance expenses, net
|
853 | 1,454 | 461 | 747 | 3,233 | |||||||||||||||
Cost of share-based payment
|
2,095 | 649 | 1,009 | 436 | 1,327 | |||||||||||||||
Loss from sale of fixed assets
|
- | 67 | - | 67 | 24 | |||||||||||||||
Taxes on income
|
34 | 36 | 11 | 12 | 73 | |||||||||||||||
Change in employee benefit liabilities, net
|
7 | 52 | 33 | 32 | 121 | |||||||||||||||
4,304 | 3,773 | 2,166 | 1,986 | 7,779 | ||||||||||||||||
Changes in asset and liability items:
|
||||||||||||||||||||
Decrease (increase) in trade receivables
|
2,764 | 1,743 | (2,472 | ) | (3,097 | ) | (3,445 | ) | ||||||||||||
Decrease (increase) in other accounts receivables
|
530 | 207 | 770 | 649 | (444 | ) | ||||||||||||||
Decrease (increase) in inventories and long-term inventories
|
(1,938 | ) | (3,315 | ) | 4,743 | (85 | ) | (1,182 | ) | |||||||||||
Decrease (increase) in deferred expenses
|
814 | 28 | 255 | 139 | (1,231 | ) | ||||||||||||||
Increase (decrease) in trade payables
|
1,898 | (3,178 | ) | (342 | ) | (3,716 | ) | 1,579 | ||||||||||||
Increase (decrease) in other accounts payables
|
196 | 960 | 759 | 1,190 | 264 | |||||||||||||||
Decrease in deferred revenues
|
(1,829 | ) | (1,485 | ) | (983 | ) | (1,351 | ) | (6,270 | ) | ||||||||||
2,435 | (5,040 | ) | 2,730 | (6,271 | ) | (10,729 | ) | |||||||||||||
Cash paid and received during the period for:
|
||||||||||||||||||||
Interest paid
|
(602 | ) | (1,062 | ) | (301 | ) | (527 | ) | (1,968 | ) | ||||||||||
Interest received
|
132 | 195 | 38 | 112 | 663 | |||||||||||||||
Taxes paid
|
(64 | ) | (54 | ) | (4 | ) | (23 | ) | (42 | ) | ||||||||||
(534 | ) | (921 | ) | (267 | ) | (438 | ) | (1,347 | ) | |||||||||||
Net cash used in operating activities
|
$ | (5,279 | ) | $ | (3,333 | ) | $ | (3,733 | ) | $ | (3,833 | ) | $ | (3,854 | ) |
Six months period Ended
June 30,
|
Three months period Ended
June 30,
|
Year Ended
December 31,
|
||||||||||||||||||
2014 | 2013 | 2014 | 2013 | 2013 | ||||||||||||||||
Unaudited | Audited | |||||||||||||||||||
Thousands of US dollar | ||||||||||||||||||||
Cash Flows from Investing Activities
|
||||||||||||||||||||
Short-term investments
|
$ | (26,784 | ) | $ | 7,848 | $ | (3,352 | ) | $ | 1,279 | $ | 1,732 | ||||||||
Purchase of property and equipment
|
(1,535 | ) | (2,747 | ) | (919 | ) | (1,473 | ) | (5,643 | ) | ||||||||||
Proceeds from sale of equipment
|
- | 3 | - | 3 | 8 | |||||||||||||||
Net cash provided by (used in) investing activities
|
(28,319 | ) | 5,104 | (4,271 | ) | (191 | ) | (3,903 | ) | |||||||||||
Cash Flows from Financing Activities
|
||||||||||||||||||||
Exercise of options into shares
|
39 | 309 | 39 | 136 | 562 | |||||||||||||||
Proceeds from issuance of ordinary shares, net
|
- | 53,958 | - | 54,479 | 52,953 | |||||||||||||||
Short term credit from bank and others, net
|
- | (6 | ) | - | (6 | ) | (12 | ) | ||||||||||||
Repayment of convertible debentures
|
- | - | - | - | (4,295 | ) | ||||||||||||||
Net cash provided by financing activities
|
39 | 54,261 | 39 | 54,609 | 49,208 | |||||||||||||||
Exchange differences on balances of cash and cash equivalent
|
(468 | ) | 505 | (266 | ) | 177 | 793 | |||||||||||||
Increase (decrease) in cash and cash equivalents
|
(34,024 | ) | 56,537 | (8,231 | ) | 50,762 | 42,244 | |||||||||||||
Cash and cash equivalents at the beginning of the period
|
59,110 | 16,866 | 33,314 | 22,641 | 16,866 | |||||||||||||||
Cash and cash equivalents at the end of the period
|
$ | 25,083 | $ | 73,403 | $ | 25,083 | $ | 73,403 | $ | 59,110 | ||||||||||
Significant non-cash transactions
|
||||||||||||||||||||
Purchase of property, equipment and intangible assets on credit
|
$ | - | $ | - | $ | - | $ | - | $ | 151 | ||||||||||
Exercise of options presented as liability
|
$ | - | $ | 23 | $ | - | $ | - | $ | 23 | ||||||||||
Exercise of convertible debentures into shares
|
$ | 7 | $ | - | $ | - | $ | - | $ | 6,508 | ||||||||||
Issuance expenses accrued in other accounts payables
|
$ | - | $ | 1,094 | $ | - | $ | 994 | $ | - |
Note 1:-
|
General
|
a.
|
IFRS 15 – Revenues from contracts with customers
IFRS 15 ("the Standard") was issued by the IASB in May 2014.
|
|
KAMADA LTD.
|
b.
|
Amendments to IAS 16 and IAS 38 - Acceptable Methods of Depreciation and Amortisation
|
|
a.
|
General:
The Company has two operating segments, as follows:
|
Proprietary Products
|
-
|
Medicine development, manufacture and sale of plasma-derived therapeutics products.
|
Distribution
|
-
|
Distribution of drugs in Israel manufacture by other companies for clinical uses, most of which are produced from plasma or its derivatives products.
|
|
b.
|
Reporting on operating segments:
|
Proprietary
Products
|
Distribution
|
Total
|
||||||||||
Unaudited
|
||||||||||||
Six months period ended June 30, 2014
|
||||||||||||
Revenues
|
$ | 16,142 | $ | 12,842 | $ | 28,984 | ||||||
Gross profit
|
$ | 1,436 | $ | 1,760 | 3,196 | |||||||
Unallocated corporate expenses
|
(13,793 | ) | ||||||||||
Finance expenses, net
|
(853 | ) | ||||||||||
Loss before taxes on income
|
$ | (11,450 | ) |
KAMADA LTD.
|
Note 4:-
|
Operating Segments (Cont.)
|
Proprietary
Products
|
Distribution
|
Total
|
||||||||||
Unaudited
|
||||||||||||
Six months period ended June 30, 2013
|
||||||||||||
Revenues
|
$ | 19,957 | $ | 8,754 | $ | 28,711 | ||||||
Gross profit
|
$ | 10,275 | $ | 1,342 | 11,617 | |||||||
Unallocated corporate expenses
|
(11,272 | ) | ||||||||||
Finance expenses, net
|
(1,454 | ) | ||||||||||
Loss before taxes on income
|
$ | (1,109 | ) |
Proprietary
Products
|
Distribution
|
Total
|
||||||||||
Unaudited
|
||||||||||||
Three months period ended June 30, 2014
|
||||||||||||
Revenues
|
$ | 8,721 | $ | 7,076 | $ | 15,797 | ||||||
Gross profit (loss)
|
$ | (982 | ) | $ | 916 | (66 | ) | |||||
Unallocated corporate expenses
|
(7,824 | ) | ||||||||||
Finance expenses, net
|
(461 | ) | ||||||||||
Loss before taxes on income
|
$ | (8,351 | ) |
Proprietary
Products
|
Distribution
|
Total
|
||||||||||
Unaudited
|
||||||||||||
Three months period ended June 30, 2013
|
||||||||||||
Revenues
|
$ | 11,897 | $ | 4,218 | $ | 16,115 | ||||||
Gross profit
|
$ | 6,776 | $ | 645 | 7,421 | |||||||
Unallocated corporate expenses
|
(5,773 | ) | ||||||||||
Finance expenses, net
|
(746 | ) | ||||||||||
Profit before taxes on income
|
$ | 902 |
Proprietary
Products
|
Distribution
|
Total
|
||||||||||
In thousands
|
||||||||||||
Audited
|
||||||||||||
Year Ended December 31, 2013
|
||||||||||||
Revenues
|
$ | 50,658 | $ | 19,965 | $ | 70,623 | ||||||
Gross profit
|
$ | 23,554 | $ | 2,853 | $ | 26,407 | ||||||
Unallocated corporate expenses
|
(22,707 | ) | ||||||||||
Finance expenses, net
|
(3,233 | ) | ||||||||||
Income before taxes on income
|
$ | 467 |
KAMADA LTD.
|
Note 5:-
|
Financial Instruments
|
|
a.
|
Classification of financial instruments by fair value hierarchy
Financial assets measured at fair value
|
Level 1
|
Level 2
|
|||||||
In thousands
|
||||||||
June 30, 2014
|
||||||||
Derivatives instruments qualified for hedging
|
$ | - | $ | 72 | ||||
Marketable securities at fair value through profit or loss:
|
||||||||
Equity shares
|
833 | - | ||||||
Mutual funds
|
2,379 | - | ||||||
Exchange traded notes
|
78 | - | ||||||
Debt securities (corporate and government)
|
10,972 | - | ||||||
14,262 | 72 | |||||||
Available for sale debt securities (corporate and government)
|
$ | - | $ | 28,341 | ||||
$ | 14,262 | $ | 28,413 | |||||
Level 1
|
Level 2
|
|||||||
In thousands
|
||||||||
June 30, 2013
|
||||||||
Derivatives instruments qualified for hedging
|
$ | - | $ | 183 | ||||
Marketable Securities (Mutual funds) at fair value through profit or loss
|
4,294 | - | ||||||
$ | 4,294 | $ | 183 | |||||
December 31, 2013
|
||||||||
Derivatives instruments qualified for hedging
|
$ | - | $ | 208 | ||||
Marketable securities at fair value through profit or loss:
|
||||||||
Equity shares
|
237 | - | ||||||
Mutual funds
|
469 | - | ||||||
Exchange traded notes
|
308 | - | ||||||
Debt securities (corporate and government)
|
4,678 | - | ||||||
5,692 | 208 | |||||||
Available for sale debt securities (corporate and government)
|
$ | - | $ | 9,375 | ||||
$ | 5,692 | $ | 9,583 |
KAMADA LTD.
|
Note 5:-
|
Financial Instruments (Cont.)
|
Level 1
|
||||
In thousands
|
||||
June 30, 2014
|
||||
Convertible debentures
|
$ | 18,528 | ||
June 30, 2013
|
||||
Convertible debentures
|
$ | 35,235 | ||
December 31, 2013
|
||||
Convertible debentures
|
$ | 24,637 |
|
b.
|
During the six months ended on June 30, 2014 there was no transfer due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument.
|
Note 6:-
|
Significant events during the period
|
|
a.
|
The Company has undertaken certain activities to increase the production capacity of its manufacturing facility in Beit Kama. A request for approval of these adjustments from the FDA was filed. In March 2013 the FDA responded to this request by requesting additional data prior to its approval of the new manufacturing process. The Company received the approval by the FDA on July 23, 2014 .During the second quarter of 2014 an inventory in the amount of $3.0 million, produced using the improved manufacturing process, was written off due to a short shelf life of the inventory and reevaluation by the Company of the fair value of such inventory.
|
|
b.
|
On January 28, 2014, General Meeting of Shareholders of the Company approved the grant of 180,000 options to the Company’s directors and the grant of 150,000 options for the Company’s chief executive officer exercisable into 330,000 ordinary shares at an exercise price of NIS 56.94. The fair value of the options was estimated at $1.8 million. The Shareholders also approved an increase in CEO monthly fixed salary to NIS 93,000 or $26,793.
|
|
c.
|
On January 29, 2014 the company incorporated a subsidiary registered under the laws of England and Wales named "Kamada Biopharma Limited".
|
|
1.
|
Summary of Financial Undertakings (according to repayment dates) as of June 30, 2014
|
a.
|
Convertible debentures issued to the public by the Company and held by the public.
|
Principal payments
|
Gross interest payments (without deduction of tax)
|
Total
|
||||||||||
ILS
|
||||||||||||
First year
|
30,247,270 | 3,035,822 | 33,283,092 | |||||||||
Second year
|
30,247,269 | 1,011,941 | 31,259,210 | |||||||||
Total
|
60,494,539 | 4,047,763 | 64,542,302 |
b.
|
Bank guarantees as of June 30, 2014, totaling US $255 thousand
|
|
2.
|
Details with Regard to Company Debentures
|
Issue Date
|
Par value at issuance (US Dollar)
|
Accumulated interest (US Dollar)
|
Book value (US Dollar) as of June 30, 2014
|
Market Value (US Dollar) as of June 30, 2014
|
Interest payment dates
|
Principal payment schedule
|
Type of interest
|
Converted to another security
|
10/18/2009
|
29,086,678
|
98,113
|
18,528,505
|
25,762,659
|
Quarterly payments on the outstanding debt, on December 1st, 2009 and on March 1st, June 1st, September 1st and December 1st of each of the years 2010 to 2015.
|
Two equal installments: of 40% each on December 1, 2014 and December 1, 2015.
|
Bears annual interest at a variable rate, plus annual margin of 6.1% above the annual interest rate for Israeli Government Debentures (Series 817) for each interest period.
|
Yes
|
|
3.
|
Details with Regard to the Trustee
|
|
4.
|
Conversion of convertible debentures
|
Security Details
|
Conversion ratio
|
Major Conversion Details
|
Ordinary shares of NIS 1 par value
|
From December 2nd, 2012 to November 15th, 2015, each NIS 37.12 par value debentures (Series C) may be convertible into one ordinary share of NIS 1 par value of the company.
|
Debentures may be converted each trading day from registration of the Debentures until November 15th, 2015 except during November 16th to December 1st of each of the years 2013 and 2014.
|
|
5.
|
At the end of the reporting period and during such reporting period the Company has complied with all the conditions and obligations under the trust deed.
|
,O&*^=\1/B]J]U\0?&%RZ?Z1#+JW_`!XZ-GM;Z5;_`/H^OS%_
MX)Y7,`_;J_:4M_.A\ZXN?&30P[_WDPAU^?S_`"/Z?EZ5^T/Q$^'$?\`@FM\&_`?BEO'
M'A#Q=\2-#\62/=/<:W9^(9H]0N?MTWG7WVZ<_P#'Q]JN.+W[57%P]Q;D4LOX
M^6<9AB+<,L)@L+A\O]OA\+'"U_;8:[]LK4$O8TE[':DG\O1XFX%XFCFO
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M/:T<57Q69_5L-7P#KXFNZ%KUU6:K4,/0I4J*56W_`"]MJ?699P[C\YXLX@SG
MBWAS+JV#Q&%P&&R2.(Q5#,/JV&H>U^LIT/8_N:^(KUJM;]UO15*GK[,_!_2$
MTW]B#_@I?'X?TVW31?AC\7DBL--L$_=Z?:6'B.'R(+R?_GWM],UCSQ_7I7Z[
M?M@E?^&8OC5(&7RV\`:\Z/\`\LY/^);/Z_RKQ7XH_P#!/'X2?&/QBWCOQ]XH
M\>:UXBCFE?3;E]8$?]CVOVS[=!9V/V?'V>WM;C_CRQ_^OT#Q3^R!X?\`&7@'
M3_AOKWQ)^)E]X7L[.ZL+R%]>\RXUBUFF\[R=4G/^DW%O;6_^B_\`7E7U>><4
M<*YWFG`N>U'Y?`G[/-]X7CACT/5G\1ZU:+"_FQH= +?CAIGA'Q!\,/#=UX4\1:E??%266'1WL)]&^SZ5+!9
M_;O)U;[1<_\`/O\`\^OVSZXZ]AX>\>VM]H<>L>*+6W\$R3:KJFFVUGK&L:;<
M?:8K'4KBQ@O()]/N;NV_TJW@^U?9>?L?GU\6>+_@A9>&OB'^SWXL\!?"3Q9<
M6>@M?W'CC['?WE_<6%M/H_V$6